Santhera Pharmaceuticals Holding Management
Management criteria checks 2/4
Santhera Pharmaceuticals Holding's CEO is Dario Eklund, appointed in Dec 2019, has a tenure of 4.92 years. total yearly compensation is CHF1.72M, comprised of 30.1% salary and 69.9% bonuses, including company stock and options. directly owns 0.037% of the company’s shares, worth CHF37.44K. The average tenure of the management team and the board of directors is 1.8 years and 4.5 years respectively.
Key information
Dario Eklund
Chief executive officer
CHF 1.7m
Total compensation
CEO salary percentage | 30.1% |
CEO tenure | 4.9yrs |
CEO ownership | 0.04% |
Management average tenure | 1.8yrs |
Board average tenure | 4.5yrs |
Recent management updates
CEO Compensation Analysis
Date | Total Compensation | Salary | Company Earnings |
---|---|---|---|
Jun 30 2024 | n/a | n/a | CHF 63m |
Mar 31 2024 | n/a | n/a | CHF 59m |
Dec 31 2023 | CHF 2m | CHF 516k | CHF 55m |
Sep 30 2023 | n/a | n/a | -CHF 5m |
Jun 30 2023 | n/a | n/a | -CHF 65m |
Mar 31 2023 | n/a | n/a | -CHF 68m |
Dec 31 2022 | CHF 2m | CHF 505k | -CHF 71m |
Sep 30 2022 | n/a | n/a | -CHF 68m |
Jun 30 2022 | n/a | n/a | -CHF 65m |
Mar 31 2022 | n/a | n/a | -CHF 60m |
Dec 31 2021 | CHF 1m | CHF 500k | -CHF 56m |
Sep 30 2021 | n/a | n/a | -CHF 56m |
Jun 30 2021 | n/a | n/a | -CHF 56m |
Mar 31 2021 | n/a | n/a | -CHF 62m |
Dec 31 2020 | CHF 681k | CHF 500k | -CHF 68m |
Sep 30 2020 | n/a | n/a | -CHF 46m |
Jun 30 2020 | n/a | n/a | -CHF 24m |
Mar 31 2020 | n/a | n/a | -CHF 21m |
Dec 31 2019 | CHF 2m | CHF 42k | -CHF 19m |
Compensation vs Market: Dario's total compensation ($USD1.94M) is above average for companies of similar size in the Swiss market ($USD809.77K).
Compensation vs Earnings: Dario's compensation has been consistent with company performance over the past year.
CEO
Dario Eklund (56 yo)
4.9yrs
Tenure
CHF 1,715,974
Compensation
Mr. Dario Eklund has been Chief Executive Officer at Santhera Pharmaceuticals Holding AG since December 1, 2019. He served as Head of Global Business Operations at Vifor Pharma Ltd. since 2014.He served a...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Founder & Chairman | 7.6yrs | CHF 200.00k | 0.26% CHF 258.6k | |
Chief Executive Officer | 4.9yrs | CHF 1.72m | 0.037% CHF 37.4k | |
Chief Financial Officer | 4.6yrs | no data | no data | |
Head of Compliance | less than a year | no data | no data | |
Head Business Development | no data | no data | 0.0083% CHF 8.3k | |
Chief Medical Officer | no data | no data | 0.022% CHF 22.0k | |
Chief Technology Officer | less than a year | no data | no data | |
Chief Legal Officer & Corporate Secretary | less than a year | no data | no data | |
Head of Global Marketing & Partner Management | no data | no data | no data | |
Head of People & Culture | 2.7yrs | no data | no data | |
Executive Vice President of Corporate Planning & Business Development | no data | no data | no data | |
Chief Commercial Officer | no data | no data | no data |
1.8yrs
Average Tenure
62yo
Average Age
Experienced Management: SANN's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Founder & Chairman | 7.6yrs | CHF 200.00k | 0.26% CHF 258.6k | |
Director | 1.4yrs | CHF 143.75k | no data | |
Director | 1.4yrs | CHF 168.75k | 0.026% CHF 25.7k | |
Non Executive Independent Director | 7.6yrs | CHF 145.00k | 0.11% CHF 112.3k |
4.5yrs
Average Tenure
59yo
Average Age
Experienced Board: SANN's board of directors are considered experienced (4.5 years average tenure).